A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer

• Status: Unknown status
• Trial end date: 2020-09-01
• Target enrollment: 0
• Participant gender: Female

Summary

This pilot trial evaluates in vivo megestrol acetate (MA) modulation of steroidal receptors in advanced breast cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Instituto Nacional de Cancer, Brazil
• Collaborator: Cancer Research UK Cambridge Institute
• Treatments: Anastrozole; Exemestane; Fulvestrant; Letrozole; Megestrol; Megestrol Acetate; Tamoxifen

Criteria

Inclusion Criteria:

• Metastatic breast cancer with ER and/or PR positive (primary tumor)

• Metastatic site amenable to biopsy

Exclusion Criteria:

• Platelet count below 100,000 / mm3

• Renal or hepatic impairment

• Coagulation disorder